Tag
This review synthesizes current evidence on the effectiveness of adjuvanted RSVPreF3 vaccination in reducing RSV-related hospitalizations among older US adults, highlighting substantial protection across high-risk subgroups.
A retrospective study of 148 state-level seasons reveals that RSV typically peaks three weeks before influenza, while COVID-19 lacks consistent seasonality, providing a critical framework for optimizing hospital resource allocation and vacc
A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the c
A comprehensive meta-analysis of over 260,000 infants confirms that nirsevimab significantly reduces respiratory syncytial virus (RSV) and lower respiratory tract infection (LRTI) hospitalizations and emergency department visits, providing
Recent real-world data from the US and France indicate that while both maternal RSV vaccination and nirsevimab are effective, nirsevimab may offer superior protection against hospitalization and intensive care admission for infants in their
The Infectious Diseases Society of America now recommends annual high-dose or adjuvanted influenza vaccine and a single RSV dose for most immunocompromised persons; timing around immunosuppression and household immunization are emphasized.
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from
This study evaluates clinical testing trends for COVID-19, influenza, and RSV among hospitalized children from 2016 to 2024, revealing shifts in testing frequency and identifying factors influencing test utilization.
Respiratory Syncytial Virus (RSV) poses serious risks to infants and older adults. Since 2023, RSV immunizations have drastically reduced hospitalizations and deaths. This article explains RSV, symptoms, immunization options, and prevention
A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.
A UK-wide multicentre study shows maternal bivalent RSV prefusion F vaccination reduces infant hospitalisation for RSV-associated ALRI by up to 72%, confirming real-world effectiveness matching clinical trials.
